Newer Anti-Hyperglycemic Agents in Type 2 Diabetes Mellitus - Expanding the Horizon

Abstract

Diabetes mellitus is a common, chronic and progressive disease resulting in micro and macrovascular complications. Many classes of drugs are available for treatment but still the search for newer anti-hyperglycemic agents continues to combat significant adverse effect profile, loss of efficacy, progressive nature of disease and improve patient compliance. New emerging therapies in pipeline include drugs targeting various pathophysiologic mechanisms like incretin based therapies, sodium glucose co-transporter inhibitors, glucokinase inhibitors, 11b hydroxy steroid dehydrogenase inhibitors, drugs modulating fatty acid metabolism, selective PPARg receptor modulators and anti inflammatory agents. Aim of this review is to describe the emerging therapies for diabetes mellitus.

QSAR Models Guided by Molecular Dynamics Applied to Human Glucokinase Activators

“…Received 16 June 2015, revised 5 October 2015 and accepted for publication 22 October 2015 Diabetes mellitus (DM) is a chronic disorder resulting from high glucose concentrations in the blood, and can be considered a global epidemic disease (1,2). Human glucokinase (GK, EC 2.7.1.2) is the principal regulating sensor of plasma glucose levels (3)(4)(5).…”